i know advanced pd'ers on generic requip, stalevo and amantadine. if you can take rytary and eliminate the amantadine and/or requip, then insco's would go for it.
$9 is similar to stalevo's price and you eliminate COMTAN side affects and insco's pay for stalevo.

whether a patient wants to wean off of an agonist is a big decision imho.

wonder if impax will conduct some trial on that switchover?